A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany

European Journal of Health Economics

Volumn 7, Issue 3, 2006, Pages 165-172

  Beard, Stephen M ^a   Maciver, Fiona ^a   Clouth, Johannes ^b   Rüther, Eckart ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b Health Outcomes ^*  (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Atypical antipsychotics; Decision support techniques; Health care costs; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DECISION MODEL; DECISION SUPPORT SYSTEM; DISEASE DURATION; DRUG COST; DRUG INDICATION; DRUG SUBSTITUTION; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; SCHIZOPHRENIA; SUICIDE; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DECISION SUPPORT TECHNIQUES; GERMANY; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA; SUICIDE; TREATMENT OUTCOME;

EID: 33750070607     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0347-0     Document Type: Article

References (24)

1. Goldner EM, Hsu L, Waraich P, Somers JM (2002) Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 47:833-843
2. Knapp M (1997) Costs of schizophrenia. Br J Psychiatry 171:509-518
3. Rice DP (1999) The economic impact of schizophrenia. J Clin Psychiatry 60 [Suppl 1]:4-6
4. Garattini L, Rossi C, Tediosi F, Cornaggia C, Covelli G, Barbui C, Parazzini F (2001) Direct costs of schizophrenia in Italian community psychiatric services. Pharmacoeconomics 19:1217-1225
5. Salize HJ (2001) Costs of schizophrenia-what we know (not)? Psychiatr Prax 28 [Suppl 1]:21-28
6. Schulenburg JM Graf von der, Uber A, Höffler J, Trenckmann U, Kissling W, Seemann U, Müller P, Rüther E (1998) Untersuchungen zu den direkten und indirekten Kosten der Schizophrenie: eine empirische Analyse. Gesundh Okon Qual Manage 381-87
7. Gerlach J (1999) The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 60 [Suppl 23]:20-24
8. National Institute of Clinical Excellence NICE (2002) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology appraisal guidance no 43, sect 1.2. NICE: London
9. Tandon R (2002) Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q 73:297-311
10. Remington G, Kapur S (2000) Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl) 148:3-15
11. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE (1998) A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manage Care 4:345-355
12. Almond S, O'Donnell O (2000) Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 17:383-389
13. Alexeyeva I, Mauskopf J, Earnshaw S, Stauffer VL, Gibson JP, Ascher-Svanum H, Ramsey J (2001) Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modelling. J Med Econ 4:179-192
14. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr (1998) Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 172:499-505
15. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:407-418
16. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:466-474
17. Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, Tran P, Catts S, Fraser A, Hustig H, Andersen S, Crawford AM (2003) Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 61-:303-314
18. Meltzer HY, Okayli G (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152:183-190
19. Montes JM, Ciudad A, Gascon J, Gomez JC EFESO Study Group (2003) Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 27:667-674
20. Anonymous (2002) Rote Liste 2002 (Online).http://www.rote-liste.de, accessed November
21. Palmer CS, Revicki DA, Halpern MT, Hatziandreu EJ (1995) The cost of suicide and suicide attempts in the United States. Clinical Neuropharmacology 18 [Suppl 3]: S25-S33
22. Revicki DA, Shakespeare A, Kind P (1996) Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 11:101-108
23. Glennie, Judith L (1997) Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia-summary. Canadian Coordinating Office for Health Technology Assessment: Ottawa
24. Deckert C, Höffler J, Kortmann J, Linden M, Roth GD, Struck M, Clouth J, Czekalla J (2001) Cost-analysis of schizophrenia treatment in Germany. a comparison of olanzapine, risperidone and haloperidol using a clinical decision model. Gesundh Okon Qual Manage 6:161-166